Joerg Schwarz, M.S., is the Senior Director of Healthcare Interoperability at Infor. He believes providers will harness the power of generative AI in 2024.
We asked our readers and some members of our editorial advisory board to make predictions for 2024. Here's what Joerg Schwarz, M.S., had to say:
"Healthcare executives are cautious about using generative artificial intelligence (AI) for clinical content, and we can expect this apprehension to extend well into 2024, primarily because of the overabundance of unstructured data. Healthcare chief information officers and chief technology officers will begin implementing a data analytics platform strategy combining data from different sources (Internet of Things, electronic health records, enterprise resource planning) in 2024, with hopes of using this platform to feed the many AI algorithms that promise improved operational and clinical outcomes.
Although healthcare providers recognize the potential of generative AI, 2024 will be the year when organizations come together and work to train algorithms for reliable results, in parallel with good governance models.”
2023 Drug Trend Report - Xevant
May 16th 2024To effectively navigate the changing pharmacy landscape and maintain a robust, cost-effective pharmacy benefit, you must understand the forces behind rising drug trend. What’s driving your costs and what can you do about it? As a leader in the PBM analytics space, we offer a unique perspective on pivotal trend drivers. Here’s what our comprehensive analysis revealed: -A surge in utilization rates across specialty and non-specialty drugs, magnified by anti-obesity therapies -Financial strain imposed by anti-inflammatory biologics and the yet-to-be-fulfilled -promise of biosimilar savings -Persistent price inflation driving higher costs year over year
Read More